Hints and tips:
Related Special Reports
...The company had previously agreed to pay up to $1.4bn to settle a long-running investigation into the sale and marketing of an opioid addiction treatment by its former subsidiary Indivior....
...It has to do with where Indivior’s growth and future growth is, which is disproportionately for us in the US markets,” said Mark Crossley, chief executive....
...Christian Heidbreder, Indivior’s chief scientific officer, said a positive outcome in the Phase 2 trial could potentially allow Indivior to negotiate with the FDA to accelerate approval of its drug....
...Indivior was spun out of consumer goods group Reckitt Benckiser in 2014 and listed on the London Stock Exchange....
...Indivior is sometimes dismissed as a single-product company with an image problem....
...Since 80 per cent of group revenues originate in the US, Indivior is exploring the option of a dual listing....
...That hope helps explain why Indivior has been spending more of its legacy drug revenue on marketing the new one. Second comes the potential for Indivior to look beyond opioids....
...Indivior suffered a revolt at its annual meeting last month when 38 per cent of votes cast went against its pay report....
...Drugmaker Indivior has announced a boardroom shake-up after making peace with its biggest shareholder....
...Indivior and its subsidiary Indivior Solutions have also previously agreed to pay $600m to resolve related liabilities....
...Indivior declined to comment beyond its statement to the market....
...The purveyor of Nurofen and Dettol is seeking to extend its £1bn indemnity claim against Indivior, a drug company it spun off in 2014....
...On the same day, more than 38 per cent of shareholders voted against drugmaker Indivior’s pay report, after it maintained bonuses for its former chief executive who was jailed for his role in the US opioids...
...At drugmaker Indivior, more than 38 per cent of shareholders voted against the company’s pay report, after it maintained bonuses for its former chief executive, despite being jailed for his role in the US...
...Mark Crossley, Indivior chief executive, said he was pleased to reach a settlement....
...The plea came as Indivior faces its own criminal trial later this year after US prosecutors indicted the company in 2019 and demanded at least $3bn in fines. Indivior has denied wrongdoing....
...Indivior, the opiate addiction treatment maker, posted a $148m net loss for 2020 on legal costs and tumbling sales of its legacy Suboxone drug....
...This subsidiary will be excluded from participating in government health programmes such as Medicaid by the US Department of Health and Human Services (HSS) but this will not apply to Indivior plc or its...
...Indivior said it “will vigorously defend itself” at trial, scheduled in May....
...Indivior had already raised guidance for the financial year in July, again citing the outperformance of Suboxone....
...Analysts at US bank Jefferies said: “While we expect this indicates a potential high water mark for Indivior, the cases are independent and Indivior is preparing to go to trial with the DoJ and any potential...
...Indivior said it remained “open to resolving the matter” and was maintaining a $438m provision “substantially related to that purpose”....
...The consumer goods maker said it had been in discussions with the US Department of Justice as part of investigations into drugmaker Indivior....
...Indivior shares rose on Thursday on stronger than expected sales of Suboxone, but Citi analysts said it was difficult to value the stock with a large potential fine hanging over it....
...Reckitt spun out the subsidiary into a separate UK-listed company called Indivior in 2014....
International Edition